As few as 5 years ago, this might have been the case, but with close to 10 novel therapies on the market it is more important than ever to know if your management of cardiovascular risk is producing the improvements you and you patients expect. With lifestyle and statins being the frontline therapies for CAD risk, it is important to know when to advance from lifestyle to medical management, as well as to know when statins alone are not producing a meaningful decrease in that risk. The only way to know whether to consider adding additional evidence-supported pharmacological interventions (ie PCSK9-inhibitors, icosapent ethyl, sodium-glucose cotransporter 2 (SGLT2) inhibitors, and others), is to visualize the disease and track it appropriately.
In his lecture on using CCTA to not only identify risk but actually track it accurately Dr. Min helps you answer the questions: Is the patient a rapid progressor? Is the therapy making a difference in the atherosclerosis? Is the therapy actually improving the stability of the plaque if not the volume? Is there a reduction in low attenuation, necrotic core plaque that is truly associated with myocardial infarction?
To better understand these questions and how to provide answers to your patients, attend Dr. Min’s lecture at … https://members.fordoctorsforum.org/